14:15884 (2022) Singh O, Panesar PS, Chopra HK
As evidenced above, it appears that tirzepatide, a peptide molecule that targets two receptors (GLP- 1 and GIP) may produce greater weight loss while producing less lean loss than GLP- 1 agonism alone, potentially by promoting fat oxidation [36]
after multiple doses, mean IGF-1 remained above baseline for up to 28 days
If treatment is appropriate, a customized semaglutide therapy plan is created with careful dosing and clear expectations
So let's take it apart properly: what microdosing actually is, what the evidence does and doesn't support, and how to tell a thoughtful low-dose plan from an expensive guess
And the worst part is you do not even know it is happening